Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 52: 1201-1202, 2006; 10.1373/clinchem.2005.064592
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winkler, C.
Right arrow Articles by Fuchs, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winkler, C.
Right arrow Articles by Fuchs, D.
Related Collections
Right arrow Clinical Immunology
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2006;52:1201-1202.)
© 2006 American Association for Clinical Chemistry, Inc.


Letters to the Editor

In Vitro Testing for Antiinflammatory Properties of Compounds

Christiana Winkler1, Florian Ueberall2 and Dietmar Fuchs1,a

1 Division of Biological Chemistry, Biocentre, Innsbruck Medical University, and, Ludwig Boltzmann Institute, of AIDS-Research, Innsbruck, Austria
2 Division of Medical Biochemistry, Biocentre, Innsbruck Medical University, Innsbruck, Austria

aAddress correspondence to this author at: Division of Biological Chemistry, Biocentre, Innsbruck Medical University, Fritz Pregl Strasse 3, Innsbruck, Austria. Fax 43-512-507-2865; e-mail dietmar.fuchs{at}uibk.ac.at.


To the Editor:

Singh et al. (1) recently proposed the application of the human myelomonocytic cell line THP-1 to test for effects of potential antiinflammatory drugs and compounds. THP-1 cells were stimulated with lipopolysaccharide for 4 to 24 h, and the secretion of proinflammatory cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor-{alpha} (TNF-{alpha}) was assessed. Results showed that various dietary supplements as well as pharmacologic agents significantly inhibited lipopolysaccharide-stimulated TNF-{alpha} release (1). Interestingly, this assay matches almost perfectly one we proposed that also uses THP-1 cells but uses neopterin production as a read-out for monitoring potential antiinflammatory effects of compounds (2). After publication of that report, we observed that drugs usually exert more important effects on the T-cell/macrophage interplay than on the stimulated monocytic cells themselves and thereby on the Th1-type cytokine interferon-{gamma}, which is crucially important as a proinflammatory mediator. Unfortunately, because we used only THP-1 cells, potential effects of compounds on the T-cell population were overlooked. Accordingly, we investigated human peripheral blood mononuclear cells (PBMCs) freshly isolated from whole blood of healthy donors and stimulated them with mitogens (3)(4)(5)(6). PBMCs were seeded at a density of 1.5 x 106 cells/mL and preincubated with compounds for 30 min before stimulation with phytohemagglutinin or concanavalin A. We found that a mitogen concentration of 10 µg/mL was optimal for detecting suppressive effects of compounds. Cells were incubated for 48 h at 37 °C and 5% CO2, and supernatants were collected thereafter. Measurements of neopterin formation by methods such as ELISA and/or tryptophan degradation by HPLC were used as convenient read-outs; both biochemical effects are induced by interferon-{gamma} in human macrophages (7).

The model system of activated PBMCs has been well established in clinical immunology for several decades and allows standardization of T-cell activation and T-cell/macrophage interaction. It is certainly more informative than the myelomonocytic tumor cell line THP-1 and more relevant for in vivo testing. Our approach has already been used for testing antiinflammatory drugs for ~5 years with very reproducible results, even between assays of blood from different donors (3)(4)(5)(6). Dose-dependent effects were detected for compounds such as resveratrol (5), drugs such as atorvastatin (4), and beverages with well-described antiatherogenic potential, such as green and black tea (3) and beer (6).

A model system that would measure products of stimulated macrophages as a read-out is clearly relevant to atherosclerosis, in which inflammation is pivotal. However, the PBMC model draws more attention to the role of T-cell/macrophage interplay, which is highly relevant in the pathogenesis of atherosclerosis, and acknowledges the existing data on the role of the proinflammatory cytokine interferon-{gamma} in the process of atherogenesis and other inflammatory conditions. By inducing the depletion of antioxidant systems and causing oxidative stress, interferon-{gamma} is probably the most important trigger for the production of reactive oxygen species in macrophages (8), considered to be of utmost relevance in atherogenesis. Our in vitro PBMC system is fully in accordance with the notion that macrophage products should be measured, and it is valid both in vitro and in vivo. Both neopterin production and tryptophan degradation are induced by interferon-{gamma} in macrophages; thus, both reflect macrophage activity. In coronary heart disease, increases in neopterin concentrations not only correlate with tryptophan degradation (9) and with the activity of the disease (9), they also predict coronary events more sensitively than do methods such as the more widely used C-reactive protein measurements (10)(11). By contrast, studies on the involvement of cytokines such as IL-1, IL-6, and TNF-{alpha} in atherogenesis stem almost exclusively from in vitro experiments.

In summary, the combined study of effects on T cells and macrophages from healthy donors appears superior to using only the myelomonocytic THP-1 cell line. The alternative approach with PBMC preparations provides insight into signaling cascades, especially those initiated by T cells. The monitoring of biochemical effects such as neopterin formation and tryptophan degradation reveals more stable results in quantitative terms than does monitoring of cytokine production. Moreover, this strategy monitors the net effect of various pro- and antiinflammatory cascades initiated during stimulated immune response in vitro and in vivo and provides data on the influence of tested compounds on the whole cascade of events. Finally, both read-out systems seem particularly suited to testing for antiinflammatory effects of compounds because enhanced production of neopterin and accelerated degradation of tryptophan are closely related to the pathogenesis of various diseases in which inflammatory processes are involved.


References

  1. Singh U, Tabibian J, Venugopal SK, Devaraj S, Jialal I. Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem 2005;51:2252-2256.[Abstract/Free Full Text]
  2. Gruber A, Murr C, Wirleitner B, Werner-Felmayer G, Fuchs D. Histamine suppresses neopterin production in the human myelomonocytoma cell line THP-1. Immunol Lett 2000;72:133-136.[Medline] [Order article via Infotrieve]
  3. Zvetkova E, Wirleitner B, Tram NT, Schennach H, Fuchs D. Aqueous extracts of Crinum latifolium (L.) and Camellia sinensis show immunomodulatory properties in human peripheral blood mononuclear cells. Intern Immunopharmacol 2001;1:2143-2150.[CrossRef]
  4. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D. Atorvastatin suppresses interferon-g-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 2003;131:264-267.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  5. Wirleitner B, Schroecksnadel K, Winkler C, Schennach H, Fuchs D. Resveratrol suppresses interferon-{gamma}-induced biochemical pathways in human peripheral blood mononuclear cells in vitro. Immunol Lett 2005;100:159-163.[CrossRef][Medline] [Order article via Infotrieve]
  6. Winkler C, Wirleitner B, Schroecksnadel K, Schennach H, Fuchs D. Beer down-regulates activated peripheral blood mononuclear cells in vitro. Intern Immunopharmacol 2006;6:390-395.[CrossRef]
  7. Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-g-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003;10:1581-1591.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  8. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-{gamma} as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983;158:670-689.[Abstract/Free Full Text]
  9. Wirleitner B, Rudzite V, Neurauter G, Murr C, Kalnins U, Erglis A, et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003;33:550-554.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  10. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005;26:457-463.[Abstract/Free Full Text]
  11. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004;110:1747-1753.[Abstract/Free Full Text]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winkler, C.
Right arrow Articles by Fuchs, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winkler, C.
Right arrow Articles by Fuchs, D.
Related Collections
Right arrow Clinical Immunology
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS